Meeder Advisory Services Inc. Makes New Investment in Edwards Lifesciences Corporation $EW

Meeder Advisory Services Inc. acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 10,516 shares of the medical research company’s stock, valued at approximately $951,000.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences during the first quarter worth $25,000. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences in the 3rd quarter valued at $25,000. MV Capital Management Inc. acquired a new position in shares of Edwards Lifesciences in the 4th quarter valued at $26,000. RMG Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of Edwards Lifesciences during the 4th quarter worth about $27,000. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 1.5%

EW opened at $92.36 on Thursday. The firm’s 50-day simple moving average is $89.03 and its 200-day simple moving average is $84.57. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $96.29. The firm has a market cap of $53.18 billion, a price-to-earnings ratio of 53.08, a PEG ratio of 2.29 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. During the same period last year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on EW shares. Piper Sandler reiterated an “overweight” rating and set a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Friday, July 17th. Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Robert W. Baird lifted their price objective on Edwards Lifesciences from $85.00 to $87.00 and gave the company a “neutral” rating in a report on Friday, April 24th. Finally, Royal Bank Of Canada upped their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average price target of $100.27.

Insider Transactions at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the sale, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 25,570 shares of company stock valued at $2,219,390. Corporate insiders own 0.31% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.